145 related articles for article (PubMed ID: 38704098)
1. IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease.
Chen CC; Buchheit KM; Lee PY; Brodeur KE; Sohail A; Cho L; Baloh CH; Balestrieri B; Derakhshan T; Feng C; Boyce JA; Dwyer DF; Laidlaw TM
J Allergy Clin Immunol; 2024 May; ():. PubMed ID: 38704098
[TBL] [Abstract][Full Text] [Related]
2. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Buchheit KM; Sohail A; Hacker J; Maurer R; Gakpo D; Bensko JC; Taliaferro F; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
[TBL] [Abstract][Full Text] [Related]
3. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Dwyer DF; Ordovas-Montanes J; Katz HR; Lewis E; Vukovic M; Lai J; Bankova LG; Bhattacharyya N; Shalek AK; Barrett NA; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2020 Jun; 145(6):1574-1584. PubMed ID: 32199912
[TBL] [Abstract][Full Text] [Related]
4. Evidence that oncostatin M synergizes with IL-4 signaling to induce TSLP expression in chronic rhinosinusitis with nasal polyps.
Wang BF; Cao PP; Norton JE; Poposki JA; Klingler AI; Suh LA; Carter R; Huang JH; Bai J; Stevens WW; Tan BK; Peters AT; Grammer LC; Conley DB; Welch KC; Liu Z; Kern RC; Kato A; Schleimer RP
J Allergy Clin Immunol; 2023 May; 151(5):1379-1390.e11. PubMed ID: 36623776
[TBL] [Abstract][Full Text] [Related]
5. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
6. Nasal polyp antibody-secreting cells display proliferation signature in aspirin-exacerbated respiratory disease.
Sohail A; Hacker J; Ryan T; McGill A; Bergmark R; Bhattacharyya N; Lee SE; Maxfield A; Roditi R; Julé AM; Griffith A; Lederer J; Laidlaw TM; Buchheit KM
J Allergy Clin Immunol; 2024 Feb; 153(2):527-532. PubMed ID: 37898408
[TBL] [Abstract][Full Text] [Related]
7. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
Machado-Carvalho L; Martín M; Torres R; Gabasa M; Alobid I; Mullol J; Pujols L; Roca-Ferrer J; Picado C
J Allergy Clin Immunol; 2016 Jan; 137(1):99-107.e7. PubMed ID: 26560040
[TBL] [Abstract][Full Text] [Related]
8. Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Wangberg H; Spierling Bagsic SR; Osuna L; White AA
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):478-484.e3. PubMed ID: 34597850
[TBL] [Abstract][Full Text] [Related]
9. Steroid affected cytokines in aspirin-exacerbated respiratory disease.
Tan LH; Lin C; Ungerer H; Kumar A; Qatanani A; Adappa ND; Palmer JN; Bosso JV; Reed D; Cohen NA; Kohanski MA
Int Forum Allergy Rhinol; 2022 Oct; 12(10):1232-1241. PubMed ID: 35032094
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
11. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
San Nicoló M; Högerle C; Gellrich D; Eder K; Pfrogner E; Gröger M
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):445-452. PubMed ID: 31655881
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
13. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
14. New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
Sehanobish E; Asad M; Jerschow E
Curr Opin Allergy Clin Immunol; 2022 Feb; 22(1):42-48. PubMed ID: 34739410
[TBL] [Abstract][Full Text] [Related]
15. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Priyadharshini VS; Jiménez-Chobillon MA; de Graaf J; Porras Gutiérrez de Velasco R; Gratziou C; Ramírez-Jiménez F; Teran LM
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439758
[TBL] [Abstract][Full Text] [Related]
17. Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.
Stevens WW; Staudacher AG; Hulse KE; Carter RG; Winter DR; Abdala-Valencia H; Kato A; Suh L; Norton JE; Huang JH; Peters AT; Grammer LC; Price CPE; Conley DB; Shintani-Smith S; Tan BK; Welch KC; Kern RC; Schleimer RP
J Allergy Clin Immunol; 2021 Feb; 147(2):600-612. PubMed ID: 32371071
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid promotes fibrinolysis and may regulate polyp formation.
Sakashita M; Takabayashi T; Imoto Y; Homma T; Yoshida K; Ogi K; Kimura Y; Kato A; Stevens WW; Smith SS; Welch KC; Norton JE; Suh LA; Carter RG; Hulse KE; Seshadri S; Min JY; Pothoven KL; Conley DB; Tan BK; Harris KE; Kern RC; Haruna S; Matsuwaki Y; Ochiai R; Fujieda S; Schleimer RP
J Allergy Clin Immunol; 2022 Nov; 150(5):1114-1124.e3. PubMed ID: 35728655
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Perić A; Gaćeša D; Cvetković G; Vojvodić D
Immun Inflamm Dis; 2023 Feb; 11(2):e791. PubMed ID: 36840483
[TBL] [Abstract][Full Text] [Related]
20. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Luskin K; Thakrar H; White A
Immunol Allergy Clin North Am; 2020 May; 40(2):329-343. PubMed ID: 32278455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
